Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors – Beigene

⟵ Back to Search Results

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Beigene Study ID

BGB-A317-209

ClinicalTrials.gov ID

NCT03736889

China Drug Trials ID

CTR20180867

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

No Study Documents